Operator fluency on fresh ground

Fresenius Medical Care AG & Co. KGaA (FMS) — this company's answers

The model's full reasoning — Q2 2018 call → NOWe need to determine if the transcript shows the dynamic described. The question asks about a "recently emerged positive element of the business" whose meaningful contribution began only within roughly the last few quarters. Analysts probe it, and management responds with unhesitating, granular operational command, answering follow-up questions with specific, present-tense working detail, while conveying that the element's contribution is still early. We need to identify what element is being probed. The transcript mentions several things: Calcimimetics transition, Care Coordination, Sound divestment, ESCOs, etc. But we need to find a recently emerged positive element that analysts probe with follow-up questions, and management gives granular operational detail. Let's scan the Q&A. The first question from Tom Jones asks about Calcimimetics revenue per treatment growth, and then about Medicare rate proposal and HIF inhibitors. Mike Brosnan answers with specific numbers: "Calcimimetics was worth about $16 for both revenue and cost per treatment rounded... Q1 was about $11 per treatment." That's specific but it's about financial impact, not operational detail. Also, Calcimimetics is not necessarily "recently emerged" - it's a transition that has been ongoing. The question asks about "recently emerged positive element" - Calcimimetics is a headwind, not positive. Next question from Veronika Dubajova asks about Europe margin and ESCOs, Patients Act, MSP extension. Rice Powell answers about ESCOs: "we're sitting in a place today where we're roughly at about 41,000 patients in the ESCOs... we don't really see this going up exponentially... until we get release from CMS..." That's about a program that has been around for a while. Not necessarily recently emerged. Next question from Patrick Wood asks about capitated rates MA and California ballot. Rice Powell answers about California: "we've budgeted money to defend ourselves... we have not put any of that in our guidance..." That's about a potential future issue, not a positive element. Next question from Lisa Clive asks about bundled rate rebase and cardiovascular/endovascular reimbursement. Mike Brosnan answers about the latter: "We're not seeing any significant change over the reimbursement rates. It's more associated with the ASE conversions and the timing..." That's about a headwind.

← Back to the full FMS analysis